Strategies For Achieving Regulatory Milestones Faster

In response to demand from pharmaceutical and biotech companies seeking efficient and cost-effective drug development to achieve their regulatory milestones faster, the contract development and manufacturing organization (CMDO) industry has scaled and grown in recent years. As a result, CDMOs have become more siloed, with separate vendors each handling different activities. However, this separation can complicate the drug development process for sponsor companies, leading to delayed timelines, increased risk, and higher costs.

Explore how partnering with a vendor that offers a drug development platform with integrated drug substance, drug product, and clinical testing activities under one organization facilitates improved communication between multidisciplinary experts and a more agile approach to pharmaceutical development.